Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
Returns on capital
Helix BioPharma Corp. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.4%
avg 6264.2%
ROIC
-33.9%
avg 6432.1%
ROA
-27.7%
avg -377.0%
Analysis
ROA is currently the strongest return metric at -27.7% versus its period average of -377.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Markus Loeffler | Chief Medical Officer | CAD 318.92K | — | — | — |
Thomas Mehrling | Chief Executive Officer & Director | CAD 318.92K | — | — | — |
Rohit Babbar | Chief Financial Officer | CAD 243.77K | — | — | — |
Veronika Kandziora | Chief Operating Officer | CAD 232.24K | — | — | — |
Davide Guggi | Chief Technology Officer | CAD 213.6K | — | — | — |
Jacek Antas | Corporate Secretary | CAD 100K | — | — | — |
Natalia L. Butterworth | Corporate Secretary | CAD 100K | — | — | — |
Helen Middleton | General Counsel | — | — | — | — |
Jessica Kourniaktis DPHIL | Director of Communications | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does Helix BioPharma Corp. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about HBP.TO's management, answered from reported figures.
Who manages HBP.TO?
Helix BioPharma Corp. (HBP.TO) lists 9 active executives. The top listed executive is Markus Loeffler, Chief Medical Officer.
Continue the stock analysis
Jump to another research area for this company.